Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AARON L ELLENBOGEN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1962472241
CMS profile
224454
Location
FARMINGTON HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$256,291.98

245 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 245 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AARON L ELLENBOGEN

NPI 1962472241 · CMS profile ID 224454

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

FARMINGTON HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 245 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962472241?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AARON L ELLENBOGEN, NPI 1962472241, CMS profile ID 224454. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 245 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962472241?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AARON L ELLENBOGEN, NPI 1962472241, CMS profile ID 224454. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 245 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962472241?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AARON L ELLENBOGEN, NPI 1962472241, CMS profile ID 224454, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 245 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1962472241?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

245 matching records · $256,291.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 245 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 245.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
MDD US Operations, LLC $0.8608/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853055591 CMS
Novartis Pharmaceuticals Corporation $14.0008/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812669827 CMS
Allergan, Inc. $750.0007/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761183 CMS
Teva Pharmaceuticals USA, Inc. $14.0007/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839498231 CMS
Teva Pharmaceuticals USA, Inc. $119.5207/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839498233 CMS
Teva Pharmaceuticals USA, Inc. $2,310.0007/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839498235 CMS
MDD US Operations, LLC $11.1607/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853055587 CMS
Allergan, Inc. $22.8307/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761181 CMS
Allergan, Inc. $750.0007/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761179 CMS
MDD US Operations, LLC $1,000.0007/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853055585 CMS
Allergan, Inc. $750.0007/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761177 CMS
Kyowa Kirin, Inc. $11.7607/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852984161 CMS
Teva Pharmaceuticals USA, Inc. $1,640.0007/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839498229 CMS
Allergan, Inc. $8.9007/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761175 CMS
Abbott Laboratories $8.0407/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833798035 CMS
LivaNova USA, Inc. $11.9207/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844261233 CMS
Kyowa Kirin, Inc. $3,100.0007/13/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852984159 CMS
Allergan, Inc. $750.0007/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761173 CMS
Allergan, Inc. $750.0007/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761171 CMS
Allergan, Inc. $1,800.0007/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761169 CMS
Allergan, Inc. $55.1807/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761167 CMS
Allergan, Inc. $19.7906/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761165 CMS
MDD US Operations, LLC $2,700.0006/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853055583 CMS
Biohaven Pharmaceuticals, Inc. $500.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852484777 CMS
UCB, Inc. $19.9006/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807369247 CMS
Adamas Pharmaceuticals, Inc. $2,880.0006/22/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834397213 CMS
MDD US Operations, LLC $22.9106/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853055581 CMS
Allergan, Inc. $750.0006/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761163 CMS
Acorda Therapeutics, Inc $3,755.0006/17/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792552885 CMS
Kyowa Kirin, Inc. $122.0206/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852984157 CMS
Allergan, Inc. $21.7606/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761161 CMS
Allergan, Inc. $23.0206/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761159 CMS
MDD US Operations, LLC $4.3906/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853055579 CMS
Allergan, Inc. $1,300.0006/03/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761157 CMS
Abbott Laboratories $10.8306/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815521173 CMS
Allergan, Inc. $14.8405/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761155 CMS
Acorda Therapeutics, Inc $2,960.0005/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792552883 CMS
Allergan, Inc. $13.9105/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761151 CMS
Allergan, Inc. $750.0005/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761153 CMS
Allergan, Inc. $19.3905/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761149 CMS
Biohaven Pharmaceuticals, Inc. $2,250.0005/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852484773 CMS
Biohaven Pharmaceuticals, Inc. $115.4805/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852484775 CMS
Acorda Therapeutics, Inc $740.0005/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792552881 CMS
Allergan, Inc. $2,400.0005/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761133 CMS
Allergan, Inc. $2,400.0005/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761135 CMS
Allergan, Inc. $163.0105/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761137 CMS
Allergan, Inc. $851.6705/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761139 CMS
Allergan, Inc. $170.7405/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761141 CMS
Allergan, Inc. $180.2205/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761143 CMS
Allergan, Inc. $5,400.0005/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792761145 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $236,620.27 415
PY2020 $203,583.40 250
PY2021 $256,291.98 245
PY2022 $185,051.58 199
PY2023 $230,070.59 254
PY2024 $175,436.09 254
PY2025 $275,693.55 262

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $197,270.90 13
PY2025 Principal investigator $2,275,308.52 263
PY2024 Principal investigator $1,616,207.26 212
PY2023 Recipient $355.00 1
PY2023 Principal investigator $2,224,425.39 104
PY2022 Recipient $351.00 2
PY2022 Principal investigator $1,585,990.63 80
PY2021 Recipient $2,404.62 2
PY2021 Principal investigator $2,298,206.33 125
PY2020 Recipient $3,676.00 1
PY2020 Principal investigator $1,313,793.13 102
PY2019 Principal investigator $1,619,637.62 174

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

276 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $350.00 12/31/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer s Disease No dispute reported 06/30/2026 1202534885
Principal investigator 1 Ipsen Innovation $98.00 12/29/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297067
Principal investigator 1 Ipsen Innovation $71.00 12/29/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297075
Principal investigator 1 Ipsen Innovation $602.00 12/24/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297033
Principal investigator 1 Ipsen Innovation $142.00 12/24/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297039
Principal investigator 1 Ipsen Innovation $42.60 12/24/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297043
Principal investigator 1 Ipsen Innovation $45.00 12/24/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297045
Principal investigator 1 Ipsen Innovation $56.80 12/24/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297065
Principal investigator 1 Ipsen Innovation $142.00 12/24/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297077
Principal investigator 1 Ipsen Innovation $71.00 12/24/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297079
Principal investigator 1 Ipsen Innovation $142.00 12/24/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297081
Principal investigator 1 Ipsen Innovation $45.00 12/24/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297083
Principal investigator 1 Ipsen Innovation $142.00 12/24/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297085
Principal investigator 1 Ipsen Innovation $150.00 12/24/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297087
Principal investigator 1 Ipsen Innovation $1,948.24 12/23/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297069
Principal investigator 1 Ipsen Innovation $1,948.24 12/23/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297073
Principal investigator 1 Genentech, Inc. $47,711.00 12/22/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640442
Principal investigator 1 Ipsen Innovation $3,756.88 12/19/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297035
Principal investigator 1 Ipsen Innovation $3,677.80 12/19/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184297041
Principal investigator 1 Ipsen Innovation $1,375.54 12/19/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297047
Principal investigator 1 Ipsen Innovation $3,692.00 12/19/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184297089
Principal investigator 1 Roche TCRC, Inc. $6,167.40 12/18/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640515
Principal investigator 1 Ipsen Innovation $380.00 12/15/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184297071
Principal investigator 1 Genentech, Inc. $338.00 12/12/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640457
Principal investigator 1 Genentech, Inc. $6,727.00 12/10/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640462
Principal investigator 1 Ipsen Innovation $45.00 12/10/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184297037
Principal investigator 1 Merz Pharmaceuticals, LLC $142.13 12/10/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647484
Principal investigator 1 Merz Pharmaceuticals, LLC $3,030.45 12/10/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647486
Recipient Amneal Pharmaceuticals LLC $312.75 12/04/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530642
Principal investigator 1 Roche TCRC, Inc. $330.00 12/04/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640520
Principal investigator 1 Genentech, Inc. $4,872.00 12/01/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211640450
Principal investigator 1 Genentech, Inc. $761.00 12/01/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640453
Principal investigator 1 Janssen Research & Development, LLC $320.00 12/01/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424878
Principal investigator 1 Janssen Research & Development, LLC $90.00 12/01/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424891
Principal investigator 1 Janssen Research & Development, LLC $15,693.00 12/01/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424908
Principal investigator 1 Janssen Research & Development, LLC $320.00 12/01/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424942
Principal investigator 1 Janssen Research & Development, LLC $4,738.00 12/01/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424952
Principal investigator 1 Janssen Research & Development, LLC $5,087.00 12/01/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424962
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,232.32 12/01/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223288975
Principal investigator 1 Ipsen Innovation $994.00 11/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296985
Principal investigator 1 Ipsen Innovation $994.00 11/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296989
Principal investigator 1 Ipsen Innovation $2,253.54 11/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297019
Principal investigator 1 Ipsen Innovation $994.00 11/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297029
Principal investigator 1 Ipsen Innovation $4,463.06 11/27/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296979
Principal investigator 1 Ipsen Innovation $5,089.28 11/27/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184297021
Principal investigator 1 Ipsen Innovation $418.90 11/27/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184297027
Principal investigator 1 Genentech, Inc. $116,324.00 11/25/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211640428
Principal investigator 1 Genentech, Inc. $10,111.27 11/25/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211640432
Principal investigator 1 Roche TCRC, Inc. $220.00 11/24/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640507
Principal investigator 1 Genentech, Inc. $4,152.00 11/20/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211640436
Principal investigator 1 Ipsen Innovation $142.00 11/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296975
Principal investigator 1 Ipsen Innovation $213.00 11/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296981
Principal investigator 1 Ipsen Innovation $142.00 11/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296983
Principal investigator 1 Ipsen Innovation $213.00 11/17/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296987
Principal investigator 1 Ipsen Innovation $156.00 11/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296991
Principal investigator 1 Ipsen Innovation $90.00 11/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296993
Principal investigator 1 Ipsen Innovation $45.00 11/17/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296995
Principal investigator 1 Ipsen Innovation $380.00 11/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296997
Principal investigator 1 Ipsen Innovation $4,238.70 11/17/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184297015
Principal investigator 1 Ipsen Innovation $56.80 11/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184297023
Principal investigator 1 Ipsen Innovation $45.00 11/17/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184297025
Principal investigator 1 Roche TCRC, Inc. $1,998.80 11/13/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640503
Principal investigator 1 Ipsen Innovation $45.00 11/12/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296977
Principal investigator 1 Ipsen Innovation $85.20 11/12/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184297011
Principal investigator 1 Ipsen Innovation $248.50 11/12/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184297013
Principal investigator 1 Ipsen Innovation $92.30 11/12/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184297017
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $800.00 11/12/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223288255
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 11/12/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223288257
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 11/12/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223288259
Recipient Amneal Pharmaceuticals LLC $22,500.00 11/06/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530634
Recipient Amneal Pharmaceuticals LLC $208.50 11/06/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530637
Principal investigator 1 ABBVIE INC. $7,726.76 10/28/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer s Disease No dispute reported 06/30/2026 1202518869
Principal investigator 1 Ipsen Innovation $3,513.08 10/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296873
Principal investigator 1 Ipsen Innovation $1,330.54 10/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296877
Principal investigator 1 Ipsen Innovation $2,690.90 10/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296883
Principal investigator 1 Ipsen Innovation $2,690.90 10/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296895
Principal investigator 1 Ipsen Innovation $994.00 10/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296907
Principal investigator 1 Ipsen Innovation $994.00 10/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296913
Principal investigator 1 Ipsen Innovation $1,330.54 10/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296927
Principal investigator 1 Ipsen Innovation $3,513.08 10/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296937
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,000.00 10/24/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235999405
Principal investigator 1 Genentech, Inc. $234.00 10/24/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211640420
Recipient Amneal Pharmaceuticals LLC $362.00 10/23/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530630
Principal investigator 1 Genentech, Inc. $115.82 10/23/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211640424
Principal investigator 1 Ipsen Innovation $56.80 10/22/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296901
Principal investigator 1 Ipsen Innovation $42.60 10/22/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296917
Principal investigator 1 Ipsen Innovation $45.00 10/22/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296939
Principal investigator 1 Ipsen Innovation $142.00 10/22/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296943
Principal investigator 1 Genentech, Inc. $10,614.00 10/21/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640417
Principal investigator 1 Ipsen Innovation $71.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296865
Principal investigator 1 Ipsen Innovation $45.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296869
Principal investigator 1 Ipsen Innovation $56.80 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296875
Principal investigator 1 Ipsen Innovation $213.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296885
Principal investigator 1 Ipsen Innovation $500.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296887
Principal investigator 1 Ipsen Innovation $45.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296889
Principal investigator 1 Ipsen Innovation $142.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296893
Principal investigator 1 Ipsen Innovation $50.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296897
Principal investigator 1 Ipsen Innovation $526.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296899
Principal investigator 1 Ipsen Innovation $142.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296909
Principal investigator 1 Ipsen Innovation $142.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296911
Principal investigator 1 Ipsen Innovation $142.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296915
Principal investigator 1 Ipsen Innovation $380.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296923
Principal investigator 1 Ipsen Innovation $142.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296925
Principal investigator 1 Ipsen Innovation $142.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296929
Principal investigator 1 Ipsen Innovation $142.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296931
Principal investigator 1 Ipsen Innovation $56.80 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296941
Principal investigator 1 Ipsen Innovation $142.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296945
Principal investigator 1 Ipsen Innovation $213.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296947
Principal investigator 1 Ipsen Innovation $2,690.90 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296949
Principal investigator 1 Ipsen Innovation $380.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296951
Principal investigator 1 Ipsen Innovation $142.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296957
Principal investigator 1 Ipsen Innovation $142.00 10/17/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296959
Principal investigator 1 Ipsen Innovation $142.00 10/16/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296871
Principal investigator 1 Ipsen Innovation $71.00 10/16/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296879
Principal investigator 1 Ipsen Innovation $142.00 10/16/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296881
Principal investigator 1 Ipsen Innovation $71.00 10/16/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296891
Principal investigator 1 Ipsen Innovation $71.00 10/16/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296905
Principal investigator 1 Ipsen Innovation $142.00 10/16/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296921
Principal investigator 1 Ipsen Innovation $71.00 10/16/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296953
Principal investigator 1 Ipsen Innovation $655.00 10/15/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296867
Principal investigator 1 Ipsen Innovation $2,431.04 10/15/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296933
Principal investigator 1 Ipsen Innovation $2,431.04 10/15/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296935
Principal investigator 1 Genentech, Inc. $96,191.00 10/14/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211640415
Principal investigator 1 Roche TCRC, Inc. $6,167.40 10/14/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640499
Principal investigator 1 Merz Pharmaceuticals, LLC $13,000.00 10/10/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647488
Recipient Amneal Pharmaceuticals LLC $9,812.01 10/09/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530626
Principal investigator 1 Ipsen Innovation $45.00 10/08/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296903
Principal investigator 1 Ipsen Innovation $500.00 10/08/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296919
Principal investigator 1 Ipsen Innovation $45.00 10/08/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296955
Principal investigator 1 Genentech, Inc. $22,811.00 10/03/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640381
Principal investigator 1 Genentech, Inc. $196.00 10/03/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211640394
Principal investigator 1 Ipsen Innovation $5,366.18 09/29/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296851
Principal investigator 1 Ipsen Innovation $418.90 09/29/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296857
Principal investigator 1 Ipsen Innovation $4,428.98 09/29/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296859
Principal investigator 1 Ipsen Innovation $14.20 09/29/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296863
Principal investigator 1 Ipsen Innovation $2,253.54 09/26/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296853
Principal investigator 1 Ipsen Innovation $994.00 09/26/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296855
Principal investigator 1 Ipsen Innovation $156.20 09/26/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296861
Principal investigator 1 Genentech, Inc. $93.00 09/25/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211640403
Principal investigator 1 Genentech, Inc. $2,511.00 09/25/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211640407
Principal investigator 1 Genentech, Inc. $123,035.00 09/24/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211640391
Principal investigator 1 Genentech, Inc. $5,252.00 09/23/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640378
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $21,500.00 09/22/2025 Non-covered Recipient Entity
University Clinical Research - Deland, Llc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235992729
Recipient Amneal Pharmaceuticals LLC $29,729.34 09/18/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530609
Recipient Amneal Pharmaceuticals LLC $3,270.67 09/18/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530613
Recipient Amneal Pharmaceuticals LLC $29,729.34 09/18/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530618
Recipient Amneal Pharmaceuticals LLC $3,270.67 09/18/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530622
Principal investigator 1 Roche TCRC, Inc. $16,503.40 09/11/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640489
Principal investigator 1 Merz Pharmaceuticals, LLC $14,200.00 09/10/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647478
Principal investigator 1 Merz Pharmaceuticals, LLC $2,250.00 09/10/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647480
Principal investigator 1 Merz Pharmaceuticals, LLC $1,800.00 09/10/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647482
Principal investigator 1 Ipsen Innovation $156.20 08/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296823
Principal investigator 1 Ipsen Innovation $994.00 08/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296827
Principal investigator 1 Ipsen Innovation $2,097.34 08/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296829
Principal investigator 1 Ipsen Innovation $994.00 08/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296835
Principal investigator 1 Ipsen Innovation $156.20 08/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296837
Principal investigator 1 Ipsen Innovation $156.20 08/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296839
Principal investigator 1 Ipsen Innovation $156.20 08/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296849
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,518.63 08/26/2025 Non-covered Recipient Entity
Quest Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235994375
Principal investigator 1 Genentech, Inc. $9,984.00 08/22/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640387
Principal investigator 1 Ipsen Innovation $300.00 08/22/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290704
Principal investigator 1 Ipsen Innovation $90.00 08/22/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290706
Principal investigator 1 Ipsen Innovation $300.00 08/22/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290708
Principal investigator 1 Ipsen Innovation $150.00 08/15/2025 Non-covered Recipient Entity
Quest Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290702
Principal investigator 1 Roche TCRC, Inc. $13,193.60 08/14/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640486
Principal investigator 1 Roche TCRC, Inc. $5,996.40 08/13/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640492
Principal investigator 1 Genentech, Inc. $16,000.00 08/12/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211640399
Recipient Amneal Pharmaceuticals LLC $48,933.56 08/06/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530593
Recipient Amneal Pharmaceuticals LLC $104.25 08/06/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530598
Recipient Amneal Pharmaceuticals LLC $48,933.56 08/06/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530602
Recipient Amneal Pharmaceuticals LLC $104.25 08/06/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530605
Principal investigator 1 Ipsen Innovation $500.00 08/04/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296821
Principal investigator 1 Ipsen Innovation $12,500.00 08/04/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296825
Principal investigator 1 Ipsen Innovation $5,366.18 08/04/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296831
Principal investigator 1 Ipsen Innovation $1,750.00 08/04/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296833
Principal investigator 1 Ipsen Innovation $5,000.00 08/04/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296841
Principal investigator 1 Ipsen Innovation $5,089.28 08/04/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296843
Principal investigator 1 Ipsen Innovation $1,000.00 08/04/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296845
Principal investigator 1 Ipsen Innovation $1,200.00 08/04/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184296847
Principal investigator 1 Janssen Research & Development, LLC $1,009.00 08/04/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424885
Principal investigator 1 Ipsen Innovation $90.00 07/31/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290692
Principal investigator 1 Ipsen Innovation $300.00 07/31/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290694
Principal investigator 1 Janssen Research & Development, LLC $21,818.00 07/31/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424935
Principal investigator 1 Ipsen Innovation $994.00 07/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296795
Principal investigator 1 Ipsen Innovation $994.00 07/28/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296797
Principal investigator 1 Ipsen Innovation $156.20 07/28/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296811
Principal investigator 1 Ipsen Innovation $270.00 07/23/2025 Non-covered Recipient Entity
Quest Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290696
Principal investigator 1 Ipsen Innovation $450.00 07/23/2025 Non-covered Recipient Entity
Quest Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290698
Principal investigator 1 Ipsen Innovation $300.00 07/23/2025 Non-covered Recipient Entity
Quest Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290700
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,982.96 07/14/2025 Non-covered Recipient Entity
Quest Research Institute
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235994377
Principal investigator 1 Ipsen Innovation $3,513.08 07/14/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296799
Principal investigator 1 Ipsen Innovation $42.60 07/14/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296801
Principal investigator 1 Ipsen Innovation $56.80 07/14/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296803
Principal investigator 1 Ipsen Innovation $3,513.08 07/14/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296805
Principal investigator 1 Ipsen Innovation $380.00 07/14/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296809
Principal investigator 1 Genentech, Inc. $3,724.00 07/09/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640373
Principal investigator 1 Genentech, Inc. $212.00 07/07/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211640369
Principal investigator 1 Ipsen Innovation $380.00 07/04/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296807
Principal investigator 1 Ipsen Innovation $2,097.34 06/30/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296769
Principal investigator 1 Ipsen Innovation $994.00 06/30/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296771
Principal investigator 1 Ipsen Innovation $2,565.94 06/30/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296773
Principal investigator 1 Ipsen Innovation $2,565.94 06/30/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296775
Principal investigator 1 Ipsen Innovation $994.00 06/30/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296779
Principal investigator 1 Ipsen Innovation $380.00 06/26/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296777
Principal investigator 1 ABBVIE INC. $1,526.96 06/18/2025 Non-covered Recipient Entity
HORIZON SOLUTIONS INC
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) No dispute reported 06/30/2026 1202492405
Principal investigator 1 ABBVIE INC. $9,350.00 06/13/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimers Disease No dispute reported 06/30/2026 1202491455
Principal investigator 1 ABBVIE INC. $2,262.00 06/13/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimers Disease No dispute reported 06/30/2026 1202491487
Principal investigator 1 Janssen Research & Development, LLC $5,577.00 06/12/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424902
Principal investigator 1 ABBVIE INC. $1,628.76 06/09/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimers Disease No dispute reported 06/30/2026 1202490675
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 06/09/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424956
Principal investigator 1 ABBVIE INC. $3,054.18 06/06/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimers Disease No dispute reported 06/30/2026 1202490637
Principal investigator 1 Genentech, Inc. $350.00 06/04/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211640343
Principal investigator 1 ABBVIE INC. $3,000.00 06/03/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202487569
Principal investigator 1 ABBVIE INC. $1,299.00 06/02/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimers Disease No dispute reported 06/30/2026 1202487323
Principal investigator 1 ABBVIE INC. $1,031.50 06/02/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimers Disease No dispute reported 06/30/2026 1202487325
Principal investigator 1 Ipsen Innovation $150.00 05/30/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290688
Principal investigator 1 Ipsen Innovation $994.00 05/28/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290686
Principal investigator 1 Roche TCRC, Inc. $12,194.20 05/28/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640477
Principal investigator 1 Genentech, Inc. $9,887.00 05/23/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640339
Principal investigator 1 ABBVIE INC. $6,200.00 05/22/2025 Non-covered Recipient Entity
HORIZON SOLUTIONS INC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202485993
Principal investigator 1 Ipsen Innovation $3,513.08 05/21/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290682
Principal investigator 1 Ipsen Innovation $634.74 05/21/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290684
Principal investigator 1 Janssen Research & Development, LLC $66,990.00 05/19/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424874
Principal investigator 1 Janssen Research & Development, LLC $90.00 05/19/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424897
Principal investigator 1 Janssen Research & Development, LLC $24,388.00 05/19/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424920
Principal investigator 1 Janssen Research & Development, LLC $81,066.00 05/19/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424967
Principal investigator 1 Eli Lilly and Company $6.72 05/16/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187888382
Principal investigator 1 Genentech, Inc. $53,293.00 05/16/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211640361
Principal investigator 1 Ipsen Innovation $380.00 05/09/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290690
Principal investigator 1 Genentech, Inc. $620.00 05/08/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640347
Principal investigator 1 Ipsen Innovation $56.80 05/07/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290680
Principal investigator 1 Genentech, Inc. $490.00 05/05/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211640353
Principal investigator 1 Genentech, Inc. $158,823.00 05/05/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640357
Principal investigator 1 Genentech, Inc. $5,922.00 05/05/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211640366
Principal investigator 1 Eli Lilly and Company $1,472.85 04/30/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187888380
Principal investigator 1 Ipsen Innovation $156.20 04/28/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290666
Principal investigator 1 Ipsen Innovation $994.00 04/28/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290670
Principal investigator 1 Ipsen Innovation $994.00 04/28/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290672
Principal investigator 1 Ipsen Innovation $300.00 04/25/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290674
Principal investigator 1 Ipsen Innovation $360.00 04/25/2025 Non-covered Recipient Entity
Quest Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290676
Principal investigator 1 Ipsen Innovation $3,655.08 04/25/2025 Non-covered Recipient Entity
Quest Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290678
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,368.00 04/25/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223278640
Principal investigator 1 Janssen Research & Development, LLC $5,162.30 04/24/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424916
Principal investigator 1 Janssen Research & Development, LLC $2,261.40 04/24/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424928
Principal investigator 1 Roche TCRC, Inc. $15,191.45 04/24/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640482
Principal investigator 1 Genentech, Inc. $140.00 04/23/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211640349
Principal investigator 1 Ipsen Innovation $3,655.08 04/23/2025 Non-covered Recipient Entity
Quest Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290668
Principal investigator 1 Eli Lilly and Company $16,413.00 04/22/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187888346
Principal investigator 1 Eli Lilly and Company $239,664.00 04/22/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187890224
Principal investigator 1 UCB SA $14,801.00 04/14/2025 Non-covered Recipient Entity
Quest Research Institute
A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease No dispute reported 06/30/2026 1246658538
Principal investigator 1 Ipsen Innovation $3,734.58 04/10/2025 Non-covered Recipient Entity
Quest Research Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184290710
Principal investigator 1 ABBVIE INC. $16,339.54 04/07/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimers Disease No dispute reported 06/30/2026 1202474818
Principal investigator 1 Roche TCRC, Inc. $3,997.60 03/20/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640468
Principal investigator 1 ABBVIE INC. $105,415.66 03/12/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer s Disease No dispute reported 06/30/2026 1202462923
Principal investigator 1 Roche TCRC, Inc. $6,592.05 02/27/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640473
Principal investigator 1 ABBVIE INC. $1,000.00 02/13/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202451842
Principal investigator 1 ABBVIE INC. $37,098.88 02/07/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer s Disease No dispute reported 06/30/2026 1202450239
Principal investigator 1 Janssen Research & Development, LLC $189,660.00 02/07/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175424946
Principal investigator 1 Eli Lilly and Company $2,285.00 01/31/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187881876
Principal investigator 1 Eli Lilly and Company $7,762.05 01/27/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187888378
Principal investigator 1 Ipsen Innovation $90.00 01/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296735
Principal investigator 1 Ipsen Innovation $3,513.08 01/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296737
Principal investigator 1 Ipsen Innovation $2,690.90 01/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296739
Principal investigator 1 Ipsen Innovation $994.00 01/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296741
Principal investigator 1 Ipsen Innovation $994.00 01/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296743
Principal investigator 1 Ipsen Innovation $1,330.54 01/27/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296745
Principal investigator 1 Ipsen Innovation $750.00 01/20/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296751
Principal investigator 1 Roche TCRC, Inc. $51,963.10 01/16/2025 Non-covered Recipient Entity
Quest Research Institute LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211640465
Principal investigator 1 Eli Lilly and Company $45,152.00 01/13/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187888736
Principal investigator 1 H. Lundbeck A S $85.00 01/13/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE - FARMINGTON HILLS
LU AF28996 IN PARTICIPANTS WITH PARKINSON'S DISEASE (PD) No dispute reported 06/30/2026 1251766497
Principal investigator 1 H. Lundbeck A S $400.00 01/13/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE - FARMINGTON HILLS
LU AF28996 IN PARTICIPANTS WITH PARKINSON'S DISEASE (PD) No dispute reported 06/30/2026 1251766515
Principal investigator 1 ABBVIE INC. $21,066.08 01/10/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer s Disease No dispute reported 06/30/2026 1202437986
Principal investigator 1 Ipsen Innovation $3,115.48 01/08/2025 Non-covered Recipient Entity
Accel Research Sites
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184296749
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $385.00 01/08/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS TAK-341 IN SUBJECTS WITH MULTIPLE SYSTEM ATROPHY No dispute reported 06/30/2026 1223273817
Principal investigator 1 Eli Lilly and Company $195,818.36 01/03/2025 Non-covered Recipient Entity
QUEST RESEARCH INSTITUTE LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187888738
Principal investigator 1 Ipsen Innovation $150.00 01/03/2025 Non-covered Recipient Entity
Accel Research Sites
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184296747